List of Excipients in Branded Drug ELTROMBOPAG OLAMINE

Generic Drugs Containing ELTROMBOPAG OLAMINE

Company	Ingredient	NDC	Excipient
AvKARE	eltrombopag	42291-932	CELLULOSE, MICROCRYSTALLINE
AvKARE	eltrombopag	42291-932	HYPROMELLOSE
AvKARE	eltrombopag	42291-932	MAGNESIUM STEARATE
AvKARE	eltrombopag	42291-932	MANNITOL

What are the Most Frequently-Used Excipients in ELTROMBOPAG OLAMINE?

# Of NDCs	Excipient
2	CALCIUM SILICATE
5	CELLULOSE, MICROCRYSTALLINE
1	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW

Eltrombopag Olamine Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Eltrombopag olamine is a differentiated oral thrombopoietin-receptor agonist whose commercial value depends on more than active-ingredient supply. The strongest formulation opportunities are low-cost generic tablets, pediatric powders, mineral-compatible dosing systems, orally disintegrating formats, and products optimized for global food and excipient constraints. The main technical challenge is the drug’s sensitivity to polyvalent cations, which can reduce exposure when eltrombopag is administered with calcium, magnesium, aluminum, iron or zinc.

What is eltrombopag olamine and where is it used?

Eltrombopag olamine is the olamine salt of eltrombopag, a small-molecule thrombopoietin-receptor agonist marketed by Novartis as Promacta in the United States and Revolade in many other markets.

The FDA-approved indications include:

• Chronic immune thrombocytopenia in adults and children age 1 year and older with inadequate response to other treatments.
• Thrombocytopenia associated with hepatitis C infection in adults to enable interferon-based therapy.
• Severe aplastic anemia in adults and pediatric patients age 2 years and older in specified treatment settings.

Eltrombopag is administered orally, generally once daily. The approved dosage varies substantially by indication, patient age, ethnicity, hepatic status and treatment response. That dose variability creates commercial value for multiple strengths and pediatric dosage forms.

Eltrombopag is a small molecule, not a biologic. Biosimilar regulation therefore does not apply. Competitive products are expected to enter through abbreviated new drug applications, hybrid applications, or other small-molecule pathways rather than biosimilar applications.

What excipients are used in approved eltrombopag products?

The principal tablet excipients are conventional direct-compression and film-coating materials. Approved products use excipient systems based on mannitol, microcrystalline cellulose, povidone, sodium starch glycolate and magnesium stearate, with a polymeric film coat that can include hypromellose, titanium dioxide, triacetin and colorants. The powder for oral suspension uses a different system centered on mannitol, sucralose and xanthan gum, according to product labeling.[1,2]

Formulation attribute	Typical approved strategy	Commercial function
Diluent	Mannitol	Tablet mass, mouthfeel and low hygroscopicity
Filler and compression aid	Microcrystalline cellulose	Mechanical strength and process robustness
Binder	Povidone K30	Granule or tablet cohesion
Disintegrant	Sodium starch glycolate	Tablet breakup and dissolution
Lubricant	Magnesium stearate	Ejection and manufacturing control
Suspension vehicle	Xanthan gum	Particle suspension and viscosity
Sweetener	Sucralose	Pediatric palatability
Film coating	Hypromellose, titanium dioxide, triacetin and colorants	Identification, handling and swallowability

The exact inactive-ingredient profile differs by strength, market and dosage form. Formulators must match the reference product’s qualitative and quantitative composition closely enough to support regulatory approval while controlling manufacturing cost and performance risk.

Why are polyvalent cations the central excipient issue?

Eltrombopag chelates polyvalent cations. Calcium, magnesium, aluminum, iron and zinc can bind the molecule in the gastrointestinal tract and reduce absorption. The FDA label instructs patients to separate eltrombopag from antacids, dairy products and mineral supplements.[1]

This interaction materially affects excipient selection. A formulation intended for direct substitution should avoid unnecessary sources of:

• Calcium salts
• Magnesium salts
• Aluminum-containing materials
• Ferrous or ferric compounds
• Zinc salts
• Mineral-containing colorants or processing aids where exposure is meaningful

The restriction is particularly important for pediatric formulations, nutritional products and chewable dosage forms. A flavored suspension or dispersible tablet that contains calcium or iron may create a clinically relevant interaction even if the excipient is otherwise pharmaceutically acceptable.

Why calcium phosphate is commercially unattractive

Dicalcium phosphate and tricalcium phosphate are common tablet fillers. They are generally inexpensive and improve powder flow and compressibility. They are poor first-choice excipients for eltrombopag because calcium can complex with the active ingredient.

Mannitol and microcrystalline cellulose provide a more suitable non-mineral filler system. Lactose may be technically feasible, but its use does not eliminate the need to assess food-related calcium exposure and formulation-specific dissolution behavior.

Why iron oxide pigments require assessment

Iron oxides are widely used as colorants and are not equivalent to soluble iron salts in gastrointestinal behavior. They should not automatically be excluded. Their use requires a targeted risk assessment covering particle size, insoluble iron content, loading level, extraction behavior and interaction studies. A colorant system with lower elemental-metal exposure may simplify regulatory and clinical justification.

What formulation patents protect eltrombopag products?

Eltrombopag protection has historically included composition-of-matter, pharmaceutical-composition, formulation and method-of-use patent positions. The primary commercial barrier is the late-2020s patent estate associated with eltrombopag and its pharmaceutical use, rather than a broad class of conventional excipients.

The main patent categories are:

Patent category	Relevance to competitors	Typical design-around path
Eltrombopag chemical and salt claims	Can restrict the active ingredient or specific salt forms	Use the approved eltrombopag olamine form under an authorized pathway
Pharmaceutical composition claims	Can cover excipient combinations, ratios or dosage forms	Use a different excipient architecture with equivalent performance
Method-of-use claims	Can affect labeled indications and dosing regimens	Seek non-infringing labeling or challenge listed use patents
Pediatric or indication-specific claims	Can delay or limit certain launches	Launch with restricted labeling or after claim expiration
Manufacturing claims	Can cover crystallization, purification or particle engineering	Use an independent process and demonstrate control of impurities

US Patent No. 7,799,782, associated with eltrombopag, has been publicly reported with an expiration date in 2027, subject to applicable patent-term adjustments or extensions. The Orange Book must be reviewed for the current listed patents, pediatric exclusivity and litigation status before a launch decision.[3,4]

The practical implication is that a generic company should not assume that a compositionally simple tablet is free of patent risk. A formulation can avoid an excipient patent while still infringing active-ingredient, salt, use or manufacturing claims.

When does eltrombopag lose exclusivity?

US regulatory exclusivity for the original Promacta approvals has expired or is no longer the principal barrier to competition. The remaining commercial protection is primarily patent-based.

Milestone	Approximate status
Initial US approval for ITP	2008
Hepatitis C thrombocytopenia approval	2012
Severe aplastic anemia approval	2014
Pediatric ITP expansion	Later supplemental approval
Core patent protection	Late 2020s, depending on patent and adjustment
Generic opportunity	Potentially before or after patent expiry through Paragraph IV litigation

The exact earliest lawful generic-entry date depends on the Orange Book listings, Paragraph IV certifications, patent litigation outcomes, settlement terms and any pediatric exclusivity. Patent expiration dates should be treated at the claim and product level rather than as a single date for all indications.

What Paragraph IV challenges and litigation risks exist?

A generic applicant can challenge listed patents by filing a Paragraph IV certification asserting that a patent is invalid, unenforceable or not infringed. The NDA holder can then bring patent litigation, triggering a potential 30-month stay of FDA approval under the Hatch-Waxman framework.[5]

The relevant risk areas include:

1. Active-ingredient and salt-form claims.
2. Pharmaceutical-composition claims.
3. Use claims covering ITP, aplastic anemia or other treatment settings.
4. Pediatric indications.
5. Manufacturing and solid-state claims.
6. Patent claims directed to the approved powder for oral suspension.

A first Paragraph IV filer may qualify for 180 days of generic exclusivity if statutory requirements are met. That period can create a significant commercial advantage because eltrombopag has a high-value specialty market and relatively limited direct competition.

Settlement agreements may permit an earlier launch before patent expiry, but the economic terms and launch date are generally company-specific. FDA approval does not itself establish freedom to operate. Regulatory approval and patent clearance are separate decisions.

What excipient strategy is best for a generic eltrombopag tablet?

A practical generic tablet strategy is a mineral-free, direct-compression or dry-granulation formulation that mirrors the reference product’s dissolution profile without copying unnecessary formulation limitations.

Recommended design objectives

• Use mannitol and microcrystalline cellulose as primary diluents.
• Use povidone or an equivalent low-level binder.
• Use sodium starch glycolate or another validated disintegrant.
• Keep magnesium stearate at the lowest level consistent with manufacturability because excess lubrication can slow dissolution.
• Avoid calcium phosphate and mineral-containing fillers.
• Control particle-size distribution and blend uniformity because eltrombopag is a low-dose, high-potency active.
• Use a film coat that does not materially alter dissolution or introduce elemental-metal concerns.
• Establish stability under high humidity, especially for low-dose strengths.

Eltrombopag’s dose range and poor aqueous solubility make dissolution method development important. A formulation may pass ordinary tablet physical tests while failing comparative dissolution under pH conditions relevant to the gastrointestinal tract.

Patent-risk advantage

A conventional tablet can support a clean design-around if it does not use a claimed excipient combination, ratio or manufacturing step. The strongest strategy is to document independent development, maintain a distinct process description and avoid unnecessary overlap with reference-product composition claims.

What pediatric formulations are protected by commercial opportunity?

The powder for oral suspension is the most attractive differentiated formulation opportunity. Pediatric patients may have difficulty swallowing tablets, and caregivers need flexible dosing and acceptable taste.

A competitive powder should provide:

• Rapid and complete dispersion.
• Low sedimentation or easy redispersion.
• Consistent dose delivery after reconstitution.
• Adequate in-use stability.
• Low microbial risk.
• Palatable flavor without mineral-containing excipients.
• A dosing syringe or calibrated measuring device.
• A reconstitution process that minimizes caregiver error.

Mannitol can provide bulk and mouthfeel, while sucralose supports sweetness. Xanthan gum can maintain suspension uniformity at low concentration. Flavor selection should account for the drug’s inherent taste, the intended pediatric age range and compatibility with the active ingredient.

A sachet-based powder that is dispersed immediately before administration may reduce preservative requirements and improve global distribution economics. A multidose bottle can be more convenient but creates greater requirements for in-use stability, redispersion and dosing accuracy.

What new dosage forms could create commercial differentiation?

Orally disintegrating tablets

An orally disintegrating tablet could improve administration for patients with dysphagia. The formulation must avoid mineral excipients and maintain rapid disintegration without compromising chemical stability.

Potential excipient systems include mannitol, crospovidone, low-substituted hydroxypropyl cellulose and taste-masking polymers. The key risk is that taste-masking coatings or particles may change dissolution and systemic exposure.

Sprinkle granules

Sprinkle granules could be administered with a small amount of non-dairy food or water. The product would require clear instructions because calcium-containing foods can reduce eltrombopag exposure. This format has commercial value only if the administration instructions are simple and clinically robust.

Lower-strength tablets

Low-strength products can support pediatric and titration markets. They may also reduce tablet splitting and dosing errors. The commercial tradeoff is higher SKU complexity and greater content-uniformity risk.

Fixed-dose combinations

Fixed-dose combinations are less attractive. Eltrombopag is used across heterogeneous treatment pathways, and many candidate partner drugs would introduce additional food, mineral or pharmacokinetic constraints. Combination products also create new patent, clinical and regulatory burdens.

How does eltrombopag compare with competing thrombopoietin-receptor agonists?

Product	Active ingredient	Route	Main excipient opportunity
Promacta/Revolade	Eltrombopag olamine	Oral	Generic tablets, pediatric suspension, ODT
Nplate	Romiplostim	Subcutaneous injection	Not a direct oral formulation competitor
Doptelet	Avatrombopag	Oral	Oral platelet-stimulation alternative with different interaction profile
Mulpleta	Lusutrombopag	Oral	Oral alternative, mainly in procedure-related thrombocytopenia

Eltrombopag’s principal commercial weakness is its cation interaction and food restrictions. Avatrombopag and lusutrombopag may be commercially preferable in settings where dosing convenience and fewer administration restrictions matter. Eltrombopag retains an opportunity in chronic ITP, pediatric treatment and severe aplastic anemia, where clinical familiarity and established dosing experience are important.

What geographic markets offer the strongest opportunity?

The US offers the highest-value abbreviated-application opportunity but also the most visible patent and litigation exposure. Europe and selected emerging markets may offer earlier commercial access where patent scope, national validation and reimbursement differ.

United States

The US opportunity is concentrated in:

• Authorized generics
• Paragraph IV launches
• Pediatric powders
• Specialty-pharmacy distribution
• Hospital and hematology contracts

Europe

European opportunities depend on country-specific patent status, centralized or national regulatory pathways, reimbursement and reference-product substitution. The brand name is generally Revolade, and national pricing pressure can be substantial.

Emerging markets

India, China, Latin America and Southeast Asia may offer volume opportunities for tablets and powders. Manufacturing barriers include impurity control, particle engineering, bioequivalence, stability in hot and humid climates, and reliable supply of high-quality excipients.

For all regions, the active ingredient’s low dose and interaction profile make analytical method validation and excipient control more important than raw tablet cost alone.

What is the commercial value of the eltrombopag market?

Promacta/Revolade has historically generated approximately billion-dollar annual sales for Novartis, placing it among the more commercially significant specialty hematology products. The main revenue exposure is in chronic ITP and severe aplastic anemia, with additional contribution from other approved uses and geographic markets.[6]

Generic price erosion will depend on:

• Number of approved competitors.
• Timing of the first Paragraph IV launch.
• Presence of an authorized generic.
• Payer substitution policies.
• Availability of pediatric dosage forms.
• Specialty-pharmacy contracting.
• Supply reliability.
• Patent settlements.

A first entrant with only standard tablets may capture the initial generic market but face rapid price erosion. A supplier with tablets, pediatric suspension and multiple strengths can defend share through portfolio breadth.

How strong is the eltrombopag patent estate?

The patent estate is commercially meaningful but not uniform across all product attributes. Active-ingredient and use claims are generally more important than conventional excipient claims. Formulation patents can still affect pediatric suspensions, dissolution profiles and specific composition designs.

Risk dimension	Assessment
Active ingredient	High relevance through late-2020s patent protection
Conventional excipients	Moderate risk, depending on listed composition claims
Pediatric suspension	Higher risk if specific composition or use claims apply
Method of use	Indication-specific risk
Manufacturing process	Relevant where solid-state or impurity claims are asserted
Biosimilar risk	Not applicable
Generic substitution	Likely pathway after patent and regulatory barriers are cleared

The best commercial strategy combines a freedom-to-operate review with formulation development that avoids unnecessary patent overlap.

Key Takeaways

• Eltrombopag olamine is an oral small molecule with no biosimilar pathway.
• The central excipient constraint is avoidance of clinically relevant polyvalent-cation interactions.
• Mannitol, microcrystalline cellulose, povidone and sodium starch glycolate provide a practical generic tablet platform.
• Calcium phosphate and other mineral-containing excipients should generally be avoided unless justified by interaction data.
• Pediatric powder for oral suspension is the strongest differentiated formulation opportunity.
• Orally disintegrating tablets, lower-strength tablets and sprinkle systems offer secondary opportunities.
• The US market presents high revenue potential but meaningful Paragraph IV and late-2020s patent risk.
• Commercial success will depend on more than tablet approval: dosage-form breadth, supply reliability, specialty distribution and patent clearance will determine market share.

FAQs

Can lactose be used in eltrombopag olamine tablets?

Lactose may be technically feasible, but formulation development must assess dissolution, stability, compatibility and the product’s administration instructions. Lactose does not remove the clinical concern associated with calcium-containing foods or supplements.

Is magnesium stearate prohibited in eltrombopag formulations?

No. Magnesium stearate is used in approved tablet formulations. The concern is not the small quantity of magnesium stearate used as a lubricant but clinically meaningful exposure to polyvalent cations capable of reducing gastrointestinal absorption.

Does eltrombopag olamine require a special bioequivalence study?

A generic applicant generally must meet the applicable FDA abbreviated-application requirements, including pharmacokinetic bioequivalence and product-quality standards. The formulation must also demonstrate appropriate comparative dissolution and control of content uniformity.

Can eltrombopag powder be mixed with milk?

Administration with calcium-containing foods or beverages can reduce eltrombopag absorption. Product labeling should provide specific instructions, and a pediatric formulation should be designed around water or another permitted vehicle rather than dairy administration.[1]

Is an eltrombopag olamine authorized generic commercially attractive?

Yes. An authorized generic can enter with lower patent risk if supplied under an agreement with the NDA holder, but its margin profile may be less favorable than an independent Paragraph IV launch. The optimal route depends on launch timing, settlement terms, manufacturing scale and payer contracting.

References

1. U.S. Food and Drug Administration. (2024). Promacta (eltrombopag) prescribing information. FDA.

2. National Library of Medicine. (2024). Promacta-eltrombopag olamine tablet and powder, for suspension. DailyMed.

3. U.S. Patent and Trademark Office. (2009). U.S. Patent No. 7,799,782, quinoline derivative. USPTO.

4. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.

6. Novartis AG. (2024). Annual report 2023. Novartis.